IL6 and rheumatoid arthritis: Furthermore, tocilizumab, an IL-6 receptor antagonist, demonstrated improvements in left ventricular ejection fraction in rheumatoid arthritis patients without overt cardiac symptoms, reinforcing the potential benefits of targeting IL-6 (95).